Skip to main content
. 2021 Mar 15;268(9):3444–3455. doi: 10.1007/s00415-021-10519-4

Table 1.

Overall sample descriptive statistics (n = 90)

Variable Mean (SD) or count (%)
Demographics
 Age 66.74 (9.22)
 Education, years 9.66 (4.09)
 Sex, male 53 (58.90%)
Clinical features
 Age at onset 61.63 (9.72)
 Disease duration, years 5.25 (2.92)
 UPDRS-III 27.33 (9.57)
 Hoehn and Yahr stage 2.00 (0.37)
 LEDD total (mg/day) 516.82 (233.37)
 LEDDDA (mg/day) 71.23 (106.27)
 LEDDL-DOPA (mg/day) 386.16 (259.29)
Behavioural measures
 Fatigue Severity Scale 3.47 (1.88)
 Beck Depression Inventory 8.91 (7.45)
 Parkinson Anxiety Scale 11.92 (9.26)
 Apathy Evaluation Scale 31.74 (7.55)
 Parkinson’s disease sleep scale 114.95 (22.23)
 Epworth Sleepiness Scale 5.77 (4.19)
Cognitive assessment
 MoCA total
  Raw score 20.02 (4.87)
  Adjusted scorea 22.46 (4.31)
  Adjusted Z scorea 0.18 (1.42)
 MoCA adjusted subscoresa
  Memory 1.29 (1.47)
  Visuospatial abilities 0.68 (1.40)
  Executive functions 0.78 (1.77)
  Attention, and WM 5.01 (1.03)
  Language 3.22 (1.52)
  Orientation 5.76 (0.57)
 PD-CFRS
  Raw 2.42 (3.01)
  Z score − 0.68 (2.32)
  MoCA (Z score) minus PD-CFRS (Z score) − 0.64 (2.30)

SD standard deviation, UPDRS Unified Parkinson’s Disease Rating Scale, LEDD levodopa equivalent daily dose, MoCA Montreal Cognitive Assessment, WM working memory, PD-CFRS Parkinson’s Disease Cognitive Functional Rating Scale

aAdjusted according to age, education, or sex